Most favored nation drug pricing lands in all 50 state Medicaid plans
Pharma CEOs say the MFN deals will hold regardless of the midterms, and manufacturers are raising European prices to defend global margins, pushing the implementation burden onto state Medicaid programs and provider pharmacy budgets.
The post-election question in biopharma was whether most favored nation drug pricing would survive a change in the political weather. Chief executives answered it in public over the past week, and the answer is yes. What matters now for health system and payer leaders is not the policy debate in Washington but the arithmetic landing in state Medicaid programs, 340B spreads and buy-and-bill margins before 2027 budgets close.
CEOs are treating MFN as settled, not provisional
Pfizer CEO Albert Bourla told Endpoints News he does not expect any changes to the signed MFN agreements, regardless of which party controls Congress. That is a notable statement from a company that spent two years arguing the policy was legally and commercially unworkable. Bayer's chief executive separately confirmed the company is still working on its own MFN arrangement with the administration, which implies the remaining holdouts are negotiating terms rather than contesting the framework.
The most revealing comment came from Sanofi. The company's CFO said Sanofi will continue launching new medicines across Europe under MFN, possibly at higher prices, rather than withholding launches to protect reference pricing. Read that in reverse and it is a confession about the US side of the ledger: if a manufacturer is willing to push European list prices up to narrow the transatlantic gap, the US discounts under MFN are real enough to be worth defending with a global repricing strategy.
Alongside this, the administration stated that all 50 states have signed up for most-favored-nation prices under Medicaid. Leaders should confirm the state count and effective dates against CMS releases before building it into a model, because the operational detail of when each state's arrangement bites will drive the timing of every downstream effect.
When a manufacturer raises European prices to defend global net price, it is confirming that the US discount is real and worth protecting.
Why European list prices are the tell
MFN math depends on reference markets, and Germany is the anchor. US trade officials held a hearing on declining German drug prices in the same window, which signals that Washington understands the reference basket is the real lever. If German prices fall, the US benchmark falls with them. If manufacturers can push European prices up, the US benchmark rises and the discount narrows without a single renegotiation in Washington.
That dynamic reframes how health care buyers should read manufacturer behavior over the next 18 months. Price increases in Europe are not a side story about foreign markets. They are the mechanism by which a US concession is partially recovered, and they put an expiration horizon on the most generous MFN-derived net prices. A formulary assumption built on today's spread may not hold in 2028.
The implementation burden lands on states and providers
Nothing about MFN in Medicaid is self-executing. State programs have to operationalize new net prices, rebate reconciliation and reporting, mostly with the same staff they had before. Health plans serving Medicaid lines will inherit the churn in supplemental rebate value, and providers will see it show up as changed economics on molecules they already dispense.
The sharpest exposure is where the same drug touches multiple payment rails. A lower Medicaid net price changes 340B spread economics on that molecule and, depending on contracting, pressures buy-and-bill margin on the Part B side. Pharmacy and finance teams that model these separately will produce two answers and act on neither. The practical fix is a single pricing-sensitivity model that runs Medicaid net, 340B acquisition and Part B reimbursement off one set of assumptions, with scenarios for a narrowing US-EU gap.
Pharma's cost offsets will reach research-active systems
Manufacturers are not absorbing the margin hit quietly. AstraZeneca has signaled that a reorganization could mean R&D reductions and trials shifted toward emerging markets, following GSK's push for roughly $1.5 billion in annual savings. Those decisions do not stay inside pharma's walls.
For academic medical centers and research-active community systems, savings programs translate into fewer sponsored trial sites, longer cycles on site payments and more studies routed offshore. Research offices should stress-test their trial portfolio pipeline for 2027 and 2028 now, and treat sponsor consolidation as a revenue risk rather than an operational nuisance. Sites that depend on two or three sponsors for the bulk of their industry-funded volume are the most exposed.
What to do before 2027 budgets lock
The window for analysis is narrow. Most systems and plans finalize 2027 assumptions in the next quarter, and MFN-derived Medicaid prices will be inside those numbers whether or not anyone modeled them deliberately.
Three concrete steps. Run a pricing-sensitivity review across Medicaid, 340B and Part B lines using a shared assumption set, not department-level spreadsheets. Build at least one scenario in which European price increases shrink the US discount by 2028, so contracting teams are not negotiating off a peak. And give research leadership a seat in the conversation, because the same policy driving your pharmacy savings is driving the sponsor budget cuts that will reach your trial sites.
